Clinical Trial: Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With Langerhans Cell in Histiocytosis (LCH)

Brief Summary: The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with Langerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-Thioguanine (6-TG) after Methotrexate (MTX).

Detailed Summary:
Sponsor: Memorial Sloan Kettering Cancer Center

Current Primary Outcome: Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential Administration of Oral 6-TG After MTX. [ Time Frame: Conclusion of the study ]

Original Primary Outcome: Determine the incidence of complete and partial response and the duration of response in patients wit hLangerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-TG after MTX. [ Time Frame: Conclusion of the study ]

Current Secondary Outcome:

Original Secondary Outcome: Define the toxicity of this sequential drug combination as defined by NCI Common Toxicity Criteria. [ Time Frame: Conclusion of study ]

Information By: Memorial Sloan Kettering Cancer Center

Dates:
Date Received: December 26, 2007
Date Started: January 1995
Date Completion:
Last Updated: April 16, 2015
Last Verified: April 2015